Q2 2025 Novocure Ltd Earnings Call Transcript
Key Points
- NovoCure Ltd (NVCR) reported a 6% increase in net revenues to $159 million, driven by a 7% year-over-year growth in active patients within their GBM franchise.
- The PANOVA-3 trial showed promising results, with TTFields therapy extending median overall survival in pancreatic cancer patients by two months compared to the control group.
- The METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer.
- NovoCure Ltd (NVCR) is making progress with regulatory submissions for new indications, including pancreatic cancer and brain metastases, with potential approvals expected in 2026.
- The company is expanding its market presence, with the launch of Optune Lua in non-small cell lung cancer in the US and Germany, and plans to launch in Japan soon.
- NovoCure Ltd (NVCR) reported a net loss of $40 million for the quarter, with a loss per share of $0.36.
- Gross margin decreased to 74% from 77% in the previous year, primarily due to the rollout of new products and the launch of non-small cell lung cancer without established reimbursement.
- The number of prescribers for non-small cell lung cancer decreased, and US prescriptions only increased by 14 sequentially, indicating slower-than-expected adoption.
- Operating expenses increased, with G&A expenses rising by 17% year-over-year, driven by higher share-based compensation and personnel costs.
- The company faces challenges in achieving profitability, with a target revenue level of $750 million needed to break even from an adjusted EBITDA perspective.
Good day. Thank you for standing by. Welcome to Novocure's second-quarter 2025 earnings conference call. (Operator Instructions) Please note that today's conference may be recorded.
I will go ahead the conference over the speaker host Ingrid Goldberg. Please go ahead.
Good morning and thank you for joining us to review Novocure's second-quarter 2025 performance. I'm on the phone this morning with our Executive Chairman, Bill Doyle; CEO, Ashley Cordova; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A. For your reference, slide accompanying this earnings release can be found on our website www.novocare.com on the Investor Relations page under Quarterly Reports.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
